Enovis (NYSE:ENOV) Director Purchases $24,877.60 in Stock

Enovis logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Enovis Director Angela Lalor bought 880 shares for $24,877.60 at an average price of $28.27, increasing her stake by 2.58% to 34,997 shares.
  • Enovis beat quarterly earnings expectations, reporting EPS of $0.88 versus the $0.77 consensus, while revenue of $558.73 million slightly exceeded estimates and rose 1.8% year over year.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $38.62; 10 analysts rate the stock Buy, one Hold, and one Sell.
  • Five stocks to consider instead of Enovis.

Enovis Corporation (NYSE:ENOV - Get Free Report) Director Angela Lalor acquired 880 shares of the business's stock in a transaction that occurred on Friday, November 13th. The shares were bought at an average price of $28.27 per share, for a total transaction of $24,877.60. Following the completion of the purchase, the director owned 34,997 shares of the company's stock, valued at approximately $989,365.19. This represents a 2.58% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Enovis Price Performance

ENOV stock traded up $0.17 during trading on Monday, hitting $27.85. The company had a trading volume of 1,258,195 shares, compared to its average volume of 1,879,055. The business has a 50 day moving average of $20.71 and a 200 day moving average of $23.25. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 8.18 and a beta of 1.31. The company has a current ratio of 2.15, a quick ratio of 1.08 and a debt-to-equity ratio of 0.82. Enovis Corporation has a fifty-two week low of $16.70 and a fifty-two week high of $31.67.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, topping analysts' consensus estimates of $0.77 by $0.11. The company had revenue of $558.73 million for the quarter, compared to the consensus estimate of $557.12 million. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. Enovis's revenue was up 1.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.75 EPS. As a group, research analysts predict that Enovis Corporation will post 3.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ENOV shares. Citigroup reaffirmed a "market outperform" rating on shares of Enovis in a research note on Wednesday, September 2nd. BMO Capital Markets set a $27.00 price objective on Enovis in a research note on Tuesday, September 1st. Wells Fargo & Company raised their target price on Enovis from $33.00 to $37.00 and gave the company an "overweight" rating in a research note on Friday, November 6th. Weiss Ratings raised Enovis from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, November 2nd. Finally, Citizens Jmp cut their price target on shares of Enovis from $55.00 to $47.00 and set a "market outperform" rating for the company in a report on Wednesday, September 2nd. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $38.62.

View Our Latest Analysis on ENOV

Institutional Investors Weigh In On Enovis

Large investors have recently modified their holdings of the stock. State of Tennessee Department of Treasury raised its position in shares of Enovis by 20.7% during the third quarter. State of Tennessee Department of Treasury now owns 21,216 shares of the company's stock worth $388,000 after purchasing an additional 3,643 shares during the period. Marshall Wace LLP lifted its holdings in shares of Enovis by 54.2% during the third quarter. Marshall Wace LLP now owns 454,094 shares of the company's stock valued at $8,296,000 after purchasing an additional 159,649 shares during the last quarter. Empowered Funds LLC acquired a new position in shares of Enovis in the 3rd quarter valued at $2,244,000. First Trust Advisors LP boosted its position in shares of Enovis by 60.2% in the 3rd quarter. First Trust Advisors LP now owns 100,117 shares of the company's stock valued at $1,829,000 after purchasing an additional 37,636 shares during the period. Finally, Public Sector Pension Investment Board increased its stake in Enovis by 66.0% in the 3rd quarter. Public Sector Pension Investment Board now owns 328,148 shares of the company's stock worth $6,223,000 after purchasing an additional 130,436 shares in the last quarter. 98.45% of the stock is owned by institutional investors.

About Enovis

(Get Free Report)

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.

Featured Articles

Insider Buying and Selling by Quarter for Enovis (NYSE:ENOV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Enovis Right Now?

Before you consider Enovis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.

While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines